{rfName}
Im

Indexed in

License and use

Citations

3

Altmetrics

Grant support

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. NR-L team is supported by the CRIS Clinical Talent Programme 2022 from 'Fundacion CRIS contra el Cancer', Instituto Carlos III and Mutua Madrilena Foundation grants (PI21/01111, AP176822021).

Analysis of institutional authors

Manso, Luis San-JoseAuthorAlfranca, ArantzazuAuthorRomero-Laorden, NuriaCorresponding Author

Share

December 16, 2024
Publications
>
Review
No

Immunome profiling in prostate cancer: a guide for clinicians

Publicated to:Frontiers in Immunology. 15 1398109- - 2024-11-20 15(), DOI: 10.3389/fimmu.2024.1398109

Authors: Manso, Luis San-Jose; Alfranca, Arantzazu; Moreno-Perez, Ignacio; Ruiz-Vico, Maria; Velasco, Clara; Toquero, Patricia; Pacheco, Maria; Zapatero, Almudena; Aldave, Diego; Celada, Guillermo; Albers, Eduardo; de la Maza, Maria-Dolores Fenor; Garcia, Jorge; Castro, Elena; Olmos, David; Colomer, Ramon; Romero-Laorden, Nuria

Affiliations

Clin Univ Navarra, Med Oncol Dept, Madrid, Spain - Author
Hosp Nino Jesus, Biocomp Unit, Inst Invest Sanitaria Princesa, Madrid, Spain - Author
Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain - Author
Hosp Univ Clin San Carlos, Med Oncol Dept, Madrid, Spain - Author
Hosp Univ La Princesa, Dept Immunol, Madrid, Spain - Author
Hosp Univ La Princesa, Radiat Oncol Dept, Madrid, Spain - Author
Hosp Univ La Princesa, Urol Dept, Madrid, Spain - Author
Hosp Univ Princesa, Med Oncol Dept, Madrid, Spain - Author
Inst Invest Sanitaria Princesa, GU Translat Res Unit, Methodol Unit, Madrid, Spain - Author
Univ Autonoma Madrid, Personalized Precis Med Chair, Madrid, Spain - Author
See more

Abstract

Tumor immune microenvironment (TIME) plays a key role to understand how tumors respond to prostate cancer (PC) therapies and potential mechanisms of resistance. Previous research has suggested that specific genomic aberrations, such as microsatellite instability (MSI) or CDK12 bi-allelic loss can allow PC patients more likely to respond to immune checkpoint inhibitors (ICI) or other immune therapies. However, responses to these treatments remain highly variable even in selected patients. Thus, it is essential to obtain more information about tumor immune cells that infiltrate these tumors, and on their plasticity and interactions, in order to better understand the underlying biology to allow development of new therapeutic strategies. This review analyzes: 1) How interactions among immune cell populations and other cells infiltrating the tumor stroma can modulate the progression of PC, 2) How the standard therapies to treat PC (such as androgen deprivation therapy, new androgen-directed hormone therapy or chemotherapy) may influence the dynamic changes of the immunome and 3) What are the limitations in characterizing the immune landscape of the hosts response to tumors.

Keywords

ActivationAndrogen deprivation therapyAnimalsAntibodBiomarkersBiomarkers, tumorCastrationCell infiltrationExpansionExpressionHumansImmune checkpoint inhibitorsImmunomeImmunophenotypeImmunotherapImmunotherapyMacrophagesMalePhase-iiPrognostic-factorProstate cancerProstatic neoplasmsTumor microenvironment

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Frontiers in Immunology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 37/181, thus managing to position itself as a Q1 (Primer Cuartil), in the category Immunology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-07-16:

  • Scopus: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 1.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 1 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 8.7.
  • The number of mentions on the social network X (formerly Twitter): 13 (Altmetric).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (SAN JOSE MANSO, LUIS ALBERTO) and Last Author (ROMERO LAORDEN, NURIA).

the author responsible for correspondence tasks has been ROMERO LAORDEN, NURIA.